col0,col1,col2,col3,col4,col5
Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis,18,colitis,"A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis",Vrije Universiteit,2022-03-31
"A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)",18,multiple myeloma,"A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety And Tolerability, Pharmacokinetics And Preliminary Efficacy of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma",Vrije Universiteit,2021-03-16
